Financhill
Buy
75

VRAI Quote, Financials, Valuation and Earnings

Last price:
$26.78
Seasonality move :
5.75%
Day range:
$27.15 - $27.15
52-week range:
$19.65 - $27.19
Dividend yield:
3.33%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
273
Avg. volume:
2.6K
1-year change:
14.96%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
VRAI
Virtus Real Asset Income ETF
-- -- -- -- --
BBC
Virtus Biotech Clinical Trials ETF
-- -- -- -- --
BBP
Virtus Biotech ETF
-- -- -- -- --
GYLD
Arrow Dow Jones Global Yield ETF
-- -- -- -- --
MDIV
First Trust Multi-Asset Diversified Income Idx Fd
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
VRAI
Virtus Real Asset Income ETF
$27.15 -- -- -- $0.14 3.33% --
BBC
Virtus Biotech Clinical Trials ETF
$42.84 -- -- -- $0.66 1.51% --
BBP
Virtus Biotech ETF
$83.70 -- -- -- $0.00 0.09% --
GYLD
Arrow Dow Jones Global Yield ETF
$13.98 -- -- -- $0.07 7.66% --
MDIV
First Trust Multi-Asset Diversified Income Idx Fd
$16.24 -- -- -- $0.13 6.28% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
VRAI
Virtus Real Asset Income ETF
-- 0.122 -- --
BBC
Virtus Biotech Clinical Trials ETF
-- 0.327 -- --
BBP
Virtus Biotech ETF
-- 0.162 -- --
GYLD
Arrow Dow Jones Global Yield ETF
-- 0.378 -- --
MDIV
First Trust Multi-Asset Diversified Income Idx Fd
-- 0.151 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
VRAI
Virtus Real Asset Income ETF
-- -- -- -- -- --
BBC
Virtus Biotech Clinical Trials ETF
-- -- -- -- -- --
BBP
Virtus Biotech ETF
-- -- -- -- -- --
GYLD
Arrow Dow Jones Global Yield ETF
-- -- -- -- -- --
MDIV
First Trust Multi-Asset Diversified Income Idx Fd
-- -- -- -- -- --

Virtus Real Asset Income ETF vs. Competitors

  • Which has Higher Returns VRAI or BBC?

    Virtus Biotech Clinical Trials ETF has a net margin of -- compared to Virtus Real Asset Income ETF's net margin of --. Virtus Real Asset Income ETF's return on equity of -- beat Virtus Biotech Clinical Trials ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VRAI
    Virtus Real Asset Income ETF
    -- -- --
    BBC
    Virtus Biotech Clinical Trials ETF
    -- -- --
  • What do Analysts Say About VRAI or BBC?

    Virtus Real Asset Income ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Real Asset Income ETF has higher upside potential than Virtus Biotech Clinical Trials ETF, analysts believe Virtus Real Asset Income ETF is more attractive than Virtus Biotech Clinical Trials ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRAI
    Virtus Real Asset Income ETF
    0 0 0
    BBC
    Virtus Biotech Clinical Trials ETF
    0 0 0
  • Is VRAI or BBC More Risky?

    Virtus Real Asset Income ETF has a beta of 0.743, which suggesting that the stock is 25.684% less volatile than S&P 500. In comparison Virtus Biotech Clinical Trials ETF has a beta of 0.974, suggesting its less volatile than the S&P 500 by 2.575%.

  • Which is a Better Dividend Stock VRAI or BBC?

    Virtus Real Asset Income ETF has a quarterly dividend of $0.14 per share corresponding to a yield of 3.33%. Virtus Biotech Clinical Trials ETF offers a yield of 1.51% to investors and pays a quarterly dividend of $0.66 per share. Virtus Real Asset Income ETF pays -- of its earnings as a dividend. Virtus Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRAI or BBC?

    Virtus Real Asset Income ETF quarterly revenues are --, which are smaller than Virtus Biotech Clinical Trials ETF quarterly revenues of --. Virtus Real Asset Income ETF's net income of -- is lower than Virtus Biotech Clinical Trials ETF's net income of --. Notably, Virtus Real Asset Income ETF's price-to-earnings ratio is -- while Virtus Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Real Asset Income ETF is -- versus -- for Virtus Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRAI
    Virtus Real Asset Income ETF
    -- -- -- --
    BBC
    Virtus Biotech Clinical Trials ETF
    -- -- -- --
  • Which has Higher Returns VRAI or BBP?

    Virtus Biotech ETF has a net margin of -- compared to Virtus Real Asset Income ETF's net margin of --. Virtus Real Asset Income ETF's return on equity of -- beat Virtus Biotech ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VRAI
    Virtus Real Asset Income ETF
    -- -- --
    BBP
    Virtus Biotech ETF
    -- -- --
  • What do Analysts Say About VRAI or BBP?

    Virtus Real Asset Income ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Real Asset Income ETF has higher upside potential than Virtus Biotech ETF, analysts believe Virtus Real Asset Income ETF is more attractive than Virtus Biotech ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRAI
    Virtus Real Asset Income ETF
    0 0 0
    BBP
    Virtus Biotech ETF
    0 0 0
  • Is VRAI or BBP More Risky?

    Virtus Real Asset Income ETF has a beta of 0.743, which suggesting that the stock is 25.684% less volatile than S&P 500. In comparison Virtus Biotech ETF has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.751%.

  • Which is a Better Dividend Stock VRAI or BBP?

    Virtus Real Asset Income ETF has a quarterly dividend of $0.14 per share corresponding to a yield of 3.33%. Virtus Biotech ETF offers a yield of 0.09% to investors and pays a quarterly dividend of $0.00 per share. Virtus Real Asset Income ETF pays -- of its earnings as a dividend. Virtus Biotech ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRAI or BBP?

    Virtus Real Asset Income ETF quarterly revenues are --, which are smaller than Virtus Biotech ETF quarterly revenues of --. Virtus Real Asset Income ETF's net income of -- is lower than Virtus Biotech ETF's net income of --. Notably, Virtus Real Asset Income ETF's price-to-earnings ratio is -- while Virtus Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Real Asset Income ETF is -- versus -- for Virtus Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRAI
    Virtus Real Asset Income ETF
    -- -- -- --
    BBP
    Virtus Biotech ETF
    -- -- -- --
  • Which has Higher Returns VRAI or GYLD?

    Arrow Dow Jones Global Yield ETF has a net margin of -- compared to Virtus Real Asset Income ETF's net margin of --. Virtus Real Asset Income ETF's return on equity of -- beat Arrow Dow Jones Global Yield ETF's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VRAI
    Virtus Real Asset Income ETF
    -- -- --
    GYLD
    Arrow Dow Jones Global Yield ETF
    -- -- --
  • What do Analysts Say About VRAI or GYLD?

    Virtus Real Asset Income ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Arrow Dow Jones Global Yield ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Real Asset Income ETF has higher upside potential than Arrow Dow Jones Global Yield ETF, analysts believe Virtus Real Asset Income ETF is more attractive than Arrow Dow Jones Global Yield ETF.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRAI
    Virtus Real Asset Income ETF
    0 0 0
    GYLD
    Arrow Dow Jones Global Yield ETF
    0 0 0
  • Is VRAI or GYLD More Risky?

    Virtus Real Asset Income ETF has a beta of 0.743, which suggesting that the stock is 25.684% less volatile than S&P 500. In comparison Arrow Dow Jones Global Yield ETF has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.658%.

  • Which is a Better Dividend Stock VRAI or GYLD?

    Virtus Real Asset Income ETF has a quarterly dividend of $0.14 per share corresponding to a yield of 3.33%. Arrow Dow Jones Global Yield ETF offers a yield of 7.66% to investors and pays a quarterly dividend of $0.07 per share. Virtus Real Asset Income ETF pays -- of its earnings as a dividend. Arrow Dow Jones Global Yield ETF pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRAI or GYLD?

    Virtus Real Asset Income ETF quarterly revenues are --, which are smaller than Arrow Dow Jones Global Yield ETF quarterly revenues of --. Virtus Real Asset Income ETF's net income of -- is lower than Arrow Dow Jones Global Yield ETF's net income of --. Notably, Virtus Real Asset Income ETF's price-to-earnings ratio is -- while Arrow Dow Jones Global Yield ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Real Asset Income ETF is -- versus -- for Arrow Dow Jones Global Yield ETF. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRAI
    Virtus Real Asset Income ETF
    -- -- -- --
    GYLD
    Arrow Dow Jones Global Yield ETF
    -- -- -- --
  • Which has Higher Returns VRAI or MDIV?

    First Trust Multi-Asset Diversified Income Idx Fd has a net margin of -- compared to Virtus Real Asset Income ETF's net margin of --. Virtus Real Asset Income ETF's return on equity of -- beat First Trust Multi-Asset Diversified Income Idx Fd's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    VRAI
    Virtus Real Asset Income ETF
    -- -- --
    MDIV
    First Trust Multi-Asset Diversified Income Idx Fd
    -- -- --
  • What do Analysts Say About VRAI or MDIV?

    Virtus Real Asset Income ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Multi-Asset Diversified Income Idx Fd has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Real Asset Income ETF has higher upside potential than First Trust Multi-Asset Diversified Income Idx Fd, analysts believe Virtus Real Asset Income ETF is more attractive than First Trust Multi-Asset Diversified Income Idx Fd.

    Company Buy Ratings Hold Ratings Sell Ratings
    VRAI
    Virtus Real Asset Income ETF
    0 0 0
    MDIV
    First Trust Multi-Asset Diversified Income Idx Fd
    0 0 0
  • Is VRAI or MDIV More Risky?

    Virtus Real Asset Income ETF has a beta of 0.743, which suggesting that the stock is 25.684% less volatile than S&P 500. In comparison First Trust Multi-Asset Diversified Income Idx Fd has a beta of 0.575, suggesting its less volatile than the S&P 500 by 42.471%.

  • Which is a Better Dividend Stock VRAI or MDIV?

    Virtus Real Asset Income ETF has a quarterly dividend of $0.14 per share corresponding to a yield of 3.33%. First Trust Multi-Asset Diversified Income Idx Fd offers a yield of 6.28% to investors and pays a quarterly dividend of $0.13 per share. Virtus Real Asset Income ETF pays -- of its earnings as a dividend. First Trust Multi-Asset Diversified Income Idx Fd pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios VRAI or MDIV?

    Virtus Real Asset Income ETF quarterly revenues are --, which are smaller than First Trust Multi-Asset Diversified Income Idx Fd quarterly revenues of --. Virtus Real Asset Income ETF's net income of -- is lower than First Trust Multi-Asset Diversified Income Idx Fd's net income of --. Notably, Virtus Real Asset Income ETF's price-to-earnings ratio is -- while First Trust Multi-Asset Diversified Income Idx Fd's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Real Asset Income ETF is -- versus -- for First Trust Multi-Asset Diversified Income Idx Fd. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    VRAI
    Virtus Real Asset Income ETF
    -- -- -- --
    MDIV
    First Trust Multi-Asset Diversified Income Idx Fd
    -- -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Celestica The Best AI Stock to Buy Now?
Is Celestica The Best AI Stock to Buy Now?

Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…

Will AI Disrupt SaaS Software Stocks?
Will AI Disrupt SaaS Software Stocks?

Since January 28th, software stocks in the United States have…

Why Is Meta Stock Going Higher?
Why Is Meta Stock Going Higher?

Over the last five days, shares of Instagram and Facebook…

Stock Ideas

Sell
46
Is NVDA Stock a Buy?

Market Cap: $4.3T
P/E Ratio: 36x

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 34x

Sell
40
Is GOOGL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 27x

Alerts

Buy
51
AAOI alert for Apr 4

Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.

Buy
59
SBAC alert for Apr 4

SBA Communications Corp. [SBAC] is up 18.96% over the past day.

Buy
55
VSAT alert for Apr 4

ViaSat, Inc. [VSAT] is up 18.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock